2. Search Result
Search Result
Results for "

NSC 681239

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

1

Isotope-Labeled Compounds

1

GMP Molecules

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-10227
    Bortezomib
    245+ Cited Publications

    PS-341; LDP-341; NSC 681239

    		 Proteasome NF-κB Apoptosis Autophagy TREM receptor Cancer
    Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
    Bortezomib
  • HY-10227R
    Bortezomib (Standard)

    PS-341 (Standard); LDP-341 (Standard); NSC 681239 (Standard)

    		 Reference Standards Proteasome NF-κB Apoptosis Autophagy TREM receptor Cancer
    Bortezomib (Standard) is the analytical standard of Bortezomib. This product is intended for research and analytical applications. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
    Bortezomib (Standard)
  • HY-10227S
    Bortezomib-d8

    PS-341-d8; LDP-341-d8; NSC 681239-d8

    		 Isotope-Labeled Compounds Proteasome NF-κB Apoptosis Autophagy TREM receptor Cancer
    Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
    Bortezomib-d8
  • HY-10227G
    Bortezomib

    PS-341; LDP-341; NSC 681239

    		 Proteasome NF-κB Apoptosis Autophagy TREM receptor Cancer
    Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
    Bortezomib

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: